Photocure ASA (OSL:PHO)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.93B |
| Revenue (ttm) | 532.58M |
| Net Income (ttm) | -1.52M |
| Shares Out | 26.61M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | 34.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 719,845 |
| Average Volume | 69,624 |
| Open | 63.50 |
| Previous Close | 64.10 |
| Day's Range | 63.40 - 79.00 |
| 52-Week Range | 47.60 - 79.80 |
| Beta | 0.37 |
| RSI | 68.15 |
| Earnings Date | Feb 18, 2026 |
About Photocure ASA
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen... [Read more]
Full Company ProfileFinancial Performance
In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.52% less than in 2024.
Financial StatementsNews
Photocure ASA reports Q4 results
PhotoCure ASA (PHCUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
PhotoCure ASA (PHCUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Photocure ASA (PHCUF) Q4 2025 Earnings Call Transcript
Photocure ASA (PHCUF) Q4 2025 Earnings Call February 18, 2026 8:00 AM ESTCompany ParticipantsDaniel Schneider - President & CEOErik Dahl - Chief...
Q4 2025 Photocure ASA Earnings Call Transcript
Q4 2025 Photocure ASA Earnings Call Transcript
Photocure ASA 2025 Q4 - Results - Earnings Call Presentation
Photocure ASA: Results for the fourth quarter of 2025
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a...
PhotoCure ASA (PHCUF) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
PhotoCure ASA (PHCUF) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Q3 2025 Photocure ASA Earnings Call Transcript
Q3 2025 Photocure ASA Earnings Call Transcript
Photocure ASA 2025 Q3 - Results - Earnings Call Presentation
Photocure ASA (PHCUF) Q3 2025 Earnings Call Transcript
Photocure ASA (OTCPK:PHCUF) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Daniel Schneider - President & CEO Erik Dahl - Chief Financial Officer Presentation Daniel Schneider...
Photocure ASA: Results for the third quarter of 2025
OSLO, Norway , Oct. 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an...
Photocure ASA: Results for the second quarter of 2025
OSLO, Norway , July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million), and ...
Photocure ASA: Results for the first quarter of 2025
OSLO, Norway , May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix ® /Cysview ® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an ...
Photocure ASA: Results for the fourth quarter of 2024
OSLO, Norway , Feb. 19, 2025 /PRNewswire/ -- Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and EBITDA...
Photocure ASA: Results for the third quarter of 2024
OSLO, Norway , Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million), and EBIT...
Photocure ASA: Results for the second quarter of 2024
OSLO, Norway , Aug. 7, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, today reported Hexvix ® /Cysview ® revenues of NOK 122.4 million in the second quarter of 2024 (Q2 20...